Send to

Choose Destination
Haematologica. 2018 May;103(5):880-889. doi: 10.3324/haematol.2017.181628. Epub 2018 Mar 15.

A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility.

Author information

Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain.
Institute of Biomedical Research of Salamanca (IBSAL), Spain.
National Medicines Institute, Warsaw, Poland.
Hematology Department, Hospital 12 de Octubre, CNIO, Complutense University, CIBERONC, Madrid, Spain.
Hospital Universitario de Salamanca, CIBERONC, Spain.
Hospital Germans Trias i Pujol, Barcelona, Spain.
Hospital Clinic, Barcelona, Spain.
Hospital 12 de Octubre, Madrid, Spain.
Clínica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain.
Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain


Protein analysis in bone marrow samples from patients with multiple myeloma has been limited by the low concentration of proteins obtained after CD138+ cell selection. A novel approach based on capillary nano-immunoassay could make it possible to quantify dozens of proteins from each myeloma sample in an automated manner. Here we present a method for the accurate and robust quantification of the expression of multiple proteins extracted from CD138-purified multiple myeloma samples frozen in RLT Plus buffer, which is commonly used for nucleic acid preservation and isolation. Additionally, the biological and clinical value of this analysis for a panel of 12 proteins essential to the pathogenesis of multiple myeloma was evaluated in 63 patients with newly diagnosed multiple myeloma. The analysis of the prognostic impact of CRBN/Cereblon and IKZF1/Ikaros mRNA/protein showed that only the protein levels were able to predict progression-free survival of patients; mRNA levels were not associated with prognosis. Interestingly, high levels of Cereblon and Ikaros proteins were associated with longer progression-free survival only in patients who received immunomodulatory drugs and not in those treated with other drugs. In conclusion, the capillary nano-immunoassay platform provides a novel opportunity for automated quantification of the expression of more than 20 proteins in CD138+ primary multiple myeloma samples.

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center